ETNB - Total Utang marang Modal 89bio Pharma

Logo perusahaan publik 89bio, Inc. (ETNB)

89bio, Inc. (ETNB) is implementing green technologies in its laboratories to minimize toxic waste and improve energy efficiency. The company is attracting leading researchers by offering creative freedom and stock options within a flexible startup environment. The business is competing for leadership in steatohepatitis therapy. This chart reflects the current market value of the total debt-to-equity ratio at 0.07, which complements the analysis of the issuer's market position.

ETNB: Total Utang marang Modal 89bio 04.07.2022 - 15.11.2025

Rincian analitis perusahaan 89bio, Inc.

- rega lan prakiraan konsensus rega:
Bagan rega 89bio|ETNB - Bagan tingkat prakiraan
- statistik kapitalisasi pasar:
Kapitalisasi pasar 89bio|ETNB - Nilai Dipunlarasaken Utang lan Kas
- indikator kapitalisasi buku:
Nilai Buku saben Saham 89bio|ETNB - Kapitalisasi Buku|Rasio Nilai Pasar marang Nilai Buku 89bio.com|ETNB - Nilai Agregat Aset
- indikator total utang lan likuiditas perusahaan:
Utang marang Ekuitas 89bio, Inc.|ETNB - Rasio utang jangka dawa marang ekuitas|Utang jangka cendhak marang modal 89bio, Inc.|ETNB - Gunggung utang perusahaan|Utang marang nilai buku 89bio|ETNB - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan 89bio|Rasio cepet 89bio.com
- informasi bathi lan kelipatan valuasi:
ETNB - Penghasilan resik perusahaan
Analisis dhasar perusahaan:89bio
Barang utama 89bio Pharma

This ratio determines the proportion of borrowed funds relative to equity, measuring the degree of financial leverage and the balance sheet's resilience to rising interest rates or market shocks. By analyzing the trend of the total debt-to-equity ratio, one can assess the ability of 89bio, Inc. (ETNB) to finance the implementation of sustainable ESG technologies and laboratory modernization without the risk of excessive debt load, which confirms the fundamental stability of the asset.

Analisis pesaing 89bio, Inc.

Utang marang Ekuitas Ascendis Pharma|Madrigal Pharmaceuticals Inc - Utang Agregat marang Ekuitas|Total Utang marang Modal CORT|RYTM (Rhythm Corp) - Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal AKRO (Akero Therapeutics)|Total Utang marang Modal metsera.com MTSR|MLTX - Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi CRNX (Crinetics Pharmaceuticals, Inc.)|NewAmsterdam Pharma N.V. (NAMS) - Utang marang Ekuitas|Rasio Total Utang marang Ekuitas Soleno Therapeutics Corp|FOLD (Amicus Therapeutics) - Total Utang marang Modal|Total Utang marang Modal agios.com|Rasio Total Utang marang Ekuitas GPCR (Structure Therapeutics Inc.)|MDXG (MiMedx Group Inc) - Rasio Kabeh Utang marang Dana Pribadi|Utang marang Ekuitas Rezolute Corp RZLT|LXRX - Rasio Total Utang marang Ekuitas|MBX Biosciences Inc - Total Utang marang Modal|Utang marang Modal altimmune.com|AARD (Aardvark Therapeutics) - Rasio Total Utang marang Ekuitas|SGMT: Utang Agregat marang Modal|BIOA (BioAge Labs Inc.) - Total Utang marang Modal|Total Utang marang Modal Biomea Fusion Corp|Total Utang marang Modal QNCX|Utang marang Ekuitas GUTS (fractyl.com)|Utang marang Ekuitas vTv Therapeutics VTVT|Agape ATP Corp (ATPC) - Utang marang Modal|PLUR - Utang marang Ekuitas|SYBX: Utang marang Ekuitas|LPCN: Total Utang marang Modal|MTNB - Koefisien Total Utang marang Modal|Utang marang Ekuitas Spruce Biosciences, Inc.|Galecto Inc (GLTO) - Koefisien Total Utang marang Modal|Utang marang Ekuitas Carmell Corp (CTCX)|Rasio Total Utang marang Ekuitas Lumos Therapeutics LUMO|Rasio Kabeh Utang marang Dana Pribadi Organovo Holdings, Inc.|Koefisien Total Utang marang Modal radiuspharm.com (RDUS)